Evelo Biosciences Inc reports results for the quarter ended in December - Earnings Summary

Evelo Biosciences

24/03/2022 13:31

* Evelo Biosciences Inc  EVLO.OQ  reported a quarterly
adjusted
loss of 54 cents​​ per share for the quarter ended in December.
The mean expectation of seven analysts for the quarter was for a
loss of 61 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * Evelo Biosciences Inc's reported EPS for the quarter was a
loss
of 54 cents​.
    * The mean earnings estimate of analysts had risen by
about 1.6%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Evelo Biosciences Inc shares had fallen by 46.1% this
quarter.
    * The company reported a quarterly loss of $28.65 million.
    * Wall Street's median 12-month price target for Evelo
Biosciences
Inc is $18.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 24 at 01:30 p.m.  ​All
figures in US dollars unless otherwise stated